Diagonal Bio AB (DIABIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Diagonal Bio AB (DIABIO) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.27 Million ≈ $-244.50K USD) by net assets (Skr26.97 Million ≈ $2.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Diagonal Bio AB - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Diagonal Bio AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Diagonal Bio AB debt and liabilities for a breakdown of total debt and financial obligations.
Diagonal Bio AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diagonal Bio AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Logistics Development Group PLC
LSE:LDG
|
-0.005x |
|
Volvere PLC
LSE:VLE
|
0.124x |
|
Thunder Power Holdings, Inc.
NASDAQ:AIEV
|
-0.049x |
|
SDM SE
XETRA:75S
|
0.321x |
|
Darmi Bersaudara Tbk PT
JK:KAYU
|
0.001x |
|
Watkin Jones PLC
LSE:WJG
|
-0.062x |
|
Alternative Income REIT PLC
LSE:AIRE
|
0.050x |
|
Yuilrobotics Co. Ltd.
KQ:388720
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Diagonal Bio AB (2020–2024)
The table below shows the annual cash flow conversion efficiency of Diagonal Bio AB from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see DIABIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr24.59 Million ≈ $2.65 Million |
Skr-13.77 Million ≈ $-1.48 Million |
-0.560x | -127.33% |
| 2023-12-31 | Skr21.25 Million ≈ $2.29 Million |
Skr-5.23 Million ≈ $-562.94K |
-0.246x | +51.22% |
| 2022-12-31 | Skr31.25 Million ≈ $3.36 Million |
Skr-15.77 Million ≈ $-1.70 Million |
-0.505x | -56.20% |
| 2021-12-31 | Skr33.87 Million ≈ $3.64 Million |
Skr-10.94 Million ≈ $-1.18 Million |
-0.323x | -1367.78% |
| 2020-12-31 | Skr8.89 Million ≈ $957.03K |
Skr226.67K ≈ $24.39K |
0.025x | -- |
About Diagonal Bio AB
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid an… Read more